Seviteronel

SKU: orb1708246

Description

Seviteronel (VT-464) is a dual-action investigational agent, functioning as both a CYP17 lyase inhibitor and an androgen receptor antagonist. It is utilized in preclinical and clinical research for hormone-driven cancers, including studies in castration-resistant prostate cancer and androgen receptor-positive breast cancer models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1610537-15-9
• MW: 399.34
• Purity: >99.99% (May vary between batches)
• Formula: C₁₈H₁₇F₄N₃O₃
• SMILES: CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1
• Target: Androgen Receptor,Cytochromes P450
• Solubility: DMSO:40 mg/mL (100.17 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.01 mM)

Bioactivity

• Target IC50:
  CYP17 Lyase (human):69 nM
• In Vivo:
  Seviteronel(100 mg/kg bid; oral administration for 25 days) reduced tumor volume in castrated male mice with xenografts.
• In Vitro:
  Seviteronel (VT-464) selectively inhibits CYP17 17,20-lyase to suppress androgen production without causing mineralocorticoid excess or cortisol depletion.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

h-CYP17 Lyase, CYP17, Androgen Receptor, AndrogenReceptor, Seviteronel, VT 464, VT464, VT-464

Compound Identifiers

PubChem CID

78357816